SMARCB1 and neoplasm: Inhibition of PD-L1 and TIGIT through atezolizumab and tiragolumab, respectively, is being examined in a phase I/II clinical trial for the treatment of relapsed or refractory SMARCB1- or SMARCA4-deficient tumours [60].